WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the ...

WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory ...

Congestion, headaches, and sinus infections burden the lives of nearly 30 million Americans suffering from chronic sinusitis each year. For Lizette Serrano, relentless allergies and asthma attacks led ...

The reimbursement rates for many ASC procedures have benefited and will benefit under the new Medicare payment system. One such procedure seeing a noticeable reimbursement boost is endoscopy with ...

A ratio of sinus scores calculated based on computed tomography (CT) imaging can accurately predict the recurrence of chronic rhinosinusitis (CRS) with nasal polyps, according to new findings. A ratio ...

Please provide your email address to receive an email when new articles are posted on . A 53-year-old female nonsmoker presented to an outpatient facility in November 2017 with 6 weeks of progressive ...

There are 4 sets of sinuses ordinarily present in humans, but congenital absence or hypoplasia of one or more sinus cavities is not uncommon. The maxillary and ethmoidal sinuses form during the third ...

A 49-year-old woman in Nevada developed foreign body (FB) sinusitis after amalgam restorative material moved from a tooth in her upper jaw into the paranasal sinuses. The case report was published ...

Paranasal sinus and nasal cavity cancer is a disease in which cancerous cells form in the tissues of the nose. Many other health problems can also cause these signs. If you have any of these signs, ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U ...

LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus ...